-
Nihon Rinsho. Japanese Journal of... 1980
Review
Topics: Action Potentials; Arrhythmias, Cardiac; Electrocardiography; Heart Conduction System; Humans; Pacemaker, Artificial
PubMed: 6997562
DOI: No ID Found -
Pediatric Clinics of North America Dec 2004Several recent technologic innovations will expand the therapeutic alternatives available to children with arrhythmia. Despite these advances, the management of these... (Review)
Review
Several recent technologic innovations will expand the therapeutic alternatives available to children with arrhythmia. Despite these advances, the management of these patients still requires a solid foundation of clinical skill and judgment. The primary care pediatric practitioner is often the first one to recognize the symptoms and signs of an arrhythmia. Careful assessment of the history, physical examination, and electrocardiogram is necessary for making the correct diagnosis.
Topics: Arrhythmias, Cardiac; Child; Child, Preschool; Diagnosis, Differential; Electrocardiography; Humans; Infant
PubMed: 15561172
DOI: 10.1016/j.pcl.2004.08.002 -
International Journal of Cardiology Jul 2020
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Catheter Ablation; Heart Failure; Humans
PubMed: 31959409
DOI: 10.1016/j.ijcard.2020.01.022 -
Deutsche Medizinische Wochenschrift... Jan 2023Tachycardiomyopathy (TMP) is the development of heart failure due to a cardiac arrhythmia - triggered by rapid and/or irregular ventricular actions. TMP is in principle...
Tachycardiomyopathy (TMP) is the development of heart failure due to a cardiac arrhythmia - triggered by rapid and/or irregular ventricular actions. TMP is in principle a (at least partially) reversible disease, so that control of the arrhythmia is of central importance. This article provides an overview of the causes, diagnosis and therapy.
Topics: Humans; Arrhythmias, Cardiac; Heart Failure; Heart Ventricles
PubMed: 36592634
DOI: 10.1055/a-1932-8085 -
Heart (British Cardiac Society) Sep 2023
Topics: Humans; Arrhythmias, Cardiac; Anti-Arrhythmia Agents; Atrial Flutter; Atrial Fibrillation
PubMed: 37770086
DOI: 10.1136/heartjnl-2023-323078 -
Praxis 2020CME ECC 67: Arrhythmia on Exertion Ventricular tachycardias are potentially life-threatening cardiac arrhythmias with a heart rate >100 beats/min, originating from the...
CME ECC 67: Arrhythmia on Exertion Ventricular tachycardias are potentially life-threatening cardiac arrhythmias with a heart rate >100 beats/min, originating from the specific conduction system below the His or the ventricular myocardium. The morphology of the surface ECG can provide valid information about the underlying mechanism and the associated cardiac disorder. The according pathomechanism is of paramount importance for further management. This article is intended to provide an insight into the various causes and treatment options as well as the differential diagnosis of ventricular tachycardias.
Topics: Arrhythmias, Cardiac; Electrocardiography; Heart Conduction System; Humans; Physical Exertion; Tachycardia, Ventricular
PubMed: 33292005
DOI: 10.1024/1661-8157/a003607 -
Journal of Cardiovascular... Jun 1993Aggravation of arrhythmia, defined as worsening of a preexisting arrhythmia or the occurrence of a new arrhythmia, is a common complication of antiarrhythmic drug... (Review)
Review
Aggravation of arrhythmia, defined as worsening of a preexisting arrhythmia or the occurrence of a new arrhythmia, is a common complication of antiarrhythmic drug therapy. Although it is largely an unpredictable event, patients at greatest risk are those with a history of congestive heart failure due to systolic dysfunction who present with a sustained ventricular tachyarrhythmia. As a rule, aggravation of arrhythmia is an early event, occurring within the first few days of initiating therapy. However, in the Cardiac Arrhythmia Suppression Trial (CAST), the increased sudden death mortality due to drug therapy, which was a result of arrhythmia aggravation, occurred throughout the entire duration of the trial, suggesting that arrhythmia aggravation can also be a late complication of therapy. Also disturbing was the fact that patients in CAST were low risk and did not have congestive heart failure or a serious ventricular tachyarrhythmia. This suggests that another important risk factor is myocardial ischemia and its potentially dangerous interaction with antiarrhythmic drugs. In patients with heart disease, especially those with coronary artery disease, antiarrhythmic drugs must therefore be used cautiously. Close and continuous follow-up is mandatory.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Risk Factors
PubMed: 8269302
DOI: 10.1111/j.1540-8167.1993.tb01233.x -
The American Journal of Cardiology Jan 1988
Review
Topics: Arrhythmias, Cardiac; Humans; Molecular Biology
PubMed: 3276122
DOI: 10.1016/0002-9149(88)90753-9 -
Nature Feb 2008Abnormalities in heart rhythm continue to cause high rates of illness and death. Better treatment could be provided by solving two main challenges: the early... (Review)
Review
Abnormalities in heart rhythm continue to cause high rates of illness and death. Better treatment could be provided by solving two main challenges: the early identification of patients who are at risk, and the characterization of molecular pathways that culminate in arrhythmias. By analysing mechanisms that increase susceptibility to arrhythmia in individuals with genetic syndromes, it might be possible to improve current therapies and to develop new ways to treat and prevent common arrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Genetic Predisposition to Disease; Humans; Myocytes, Cardiac; Syndrome
PubMed: 18288182
DOI: 10.1038/nature06799 -
Annals of Internal Medicine Oct 1980Since the original description by Dessertenne, predominantly European literature has reported the features of the unusual ventricular arrhythmia "les torsades de... (Review)
Review
Since the original description by Dessertenne, predominantly European literature has reported the features of the unusual ventricular arrhythmia "les torsades de pointes." Named because of the way the polarity of the QRS complexes seems to spiral around the baseline of the ECG, this arrhythmia is virtually always associated with prolongation of the Q-T interval. Its importance lies not in its unusual structure but in the potentially fatal outcome if conventional treatment is administered. Antiarrhythmic drugs that further prolong the Q-T interval frequently aggravate the arrhythmia and are contraindicated. Overdrive pacing, preferably atrial, is the treatment of choice with attention to any correctable causes of associated Q-T prolongation. Electrophysiologic studies so far favor a re-entrant cause for the arrhythmia, but the exact mechanism and its true relation to both conventional ventricular tachycardia and ventricular fibrillation remain to be defined.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Diagnosis, Differential; Electrocardiography; Electrophysiology; Female; Heart Ventricles; Humans; Pacemaker, Artificial; Tachycardia; Ventricular Fibrillation
PubMed: 7001975
DOI: 10.7326/0003-4819-93-4-578